Serum Levels of Angiopoietin-1, Angiopoietin-2, and Their Receptor Tie-2 in Patients with Nonsmall Cell Lung Cancer During Chemotherapy

This pilot study was conducted to investigate the prognostic role and the effects of chemotherapy on serum angiogenic factors enzyme-linked immunosorbent assay consisting of Angiopoietin-1 and 2 (Ang-1, Ang-2) and their receptor Tie-2 in patients with advanced stage nonsmall cell lung cancer (NSCLC). Concentration of Ang-2 was higher in NSCLC (n= 40) than in healthy people (n= 15), whereas Ang-1 and Tie-2 were comparable. In our opinion determination of Ang-1, Ang-2, and Tie-2 concentrations have no clinical significance in the prognosis of the survival time in lung cancer and can not be used as a predictor of response to the chemotherapy.

[1]  Y. Diao,et al.  Role of serum angiopoietin‐2 level in screening for esophageal squamous cell cancer and its precursors , 2007, Chinese medical journal.

[2]  K. Lee,et al.  Serum angiopoietin-2 as a clinical marker for lung cancer. , 2007, Chest.

[3]  T. Stępień,et al.  Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. , 2006, Cytokine.

[4]  A. Allegra,et al.  Differential levels of soluble angiopoietin‐2 and Tie‐2 in patients with haematological malignancies , 2006, European journal of haematology.

[5]  Zhi-su Liu,et al.  Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[6]  Y. Amo,et al.  Observations on angiopoietin 2 in patients with angiosarcoma , 2004, The British journal of dermatology.

[7]  A. Blann,et al.  Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1 , 2003, European journal of clinical investigation.

[8]  L. Ellis,et al.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.

[9]  S. Leung,et al.  The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. , 2000, Lung cancer.

[10]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[11]  M. Makuuchi,et al.  Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.

[12]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[13]  K. Peters.  Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. , 1998, Circulation research.

[14]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[15]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[16]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[17]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[18]  M. Dewhirst,et al.  Functional significance of Tie2 signaling in the adult vasculature. , 2004, Recent progress in hormone research.

[19]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.